Xing-chao Liu

Xing-chao Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YLYuan Li
Yuan Li
WZWei-Wei Zhou
Wei-Wei Zhou
JSJia-Huan Sun
Jia-Huan Sun
HYHong-Xia Yang
Hong-Xia Yang
GXGeng-Rui Xu
Geng-Rui Xu
ALAi-Ying Li
Ai-Ying Li
Modified citrus pectin (MCP) is a specific inhibitor of galectin-3 (Gal-3) that is regarded as a new biomarker of cardiac hypertrophy, but its effect is unclear. The aim of this study is to investigate the role and mechanism of MCP in isoproterenol (ISO)-induced cardiac hypertrophy. Rats were injected with ISO to induce cardiac hypertrophy and treated with MCP. Cardiac function was detected by ECG and echocardiography. Pathomorphological changes were evaluated by the haematoxylin eosin (H&E) and wheat germ agglutinin (WGA) staining. The hypertrophy-related genes for atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and β-myosin heavy chain (β-MHC), and the associated signal molecules were analysed by qRT-PCR and western blotting. The results show that MCP prevented cardiac hypertrophy and ameliorated cardiac dysfunction and structural disorder. MCP also decreased the levels of ANP, BNP, and β-MHC and inhibited the expression of Gal-3 and Toll-like receptor 4 (TLR4). Additionally, MCP blocked the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3), but it promoted the phosphorylation of p38. Thus, MCP prevented ISO-induced cardiac hypertrophy by activating p38 signalling and inhibiting the Gal-3/TLR4/JAK2/STAT3 pathway.

17 June 2023 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ZYZe-Qi Yang
Ze-Qi Yang
YHYang-Yang Han
Yang-Yang Han
FGFan Gao
Fan Gao
JTJia-Ye Tian
Jia-Ye Tian
RBRan Bai
Ran Bai
XLXing-chao Liu
Xing-chao Liu
Background: Chronic heart failure (CHF) is actually a disease caused by an imbalanced energy metabolism between myocardial energy demand and supply, ultimately resulting in abnormal myocardial cell structure and function. Energy metabolism imbalance plays an important role in the pathological process of chronic heart failure (CHF). Improving myocardial energy metabolism is a new strategy for the treatment of CHF. Shengxian decoction (SXT), a well-known traditional Chinese medicine (TCM) formula, has good therapeutic effects on the cardiovascular system. However, the effects of SXT on the energy metabolism of CHF is unclear. In this study, we probed the regulating effects of SXT on energy metabolism in CHF rats using various research methods. Methods: High-performance liquid chromatography (HPLC) analysis was used to perform quality control of SXT preparations. Then, SD rats were randomly assigned into 6 groups: sham, model, positive control (trimetazidine) and high-, middle-, and low-dose SXT groups. Specific reagent kits were used to detect the expression levels of ALT and AST in rats’ serum. Echocardiography was used to evaluate cardiac function. H&E, Masson and TUNEL staining were performed to examine myocardial structure and myocardial apoptosis. Colorimetry was used to determine myocardial ATP levels in experimental rats. Transmission electron microscopy was used to observe the ultrastructure of myocardial mitochondria. ELISA was used to estimate CK, cTnI, and NT-proBNP levels, and LA、FFA、MDA、SOD levels. Finally, Western blotting was used to examine the protein expression of CPT-1, GLUT4, AMPK, p-AMPK, PGC-1α, NRF1, mtTFA and ATP5D in the myocardium. Results: HPLC showed that our SXT preparation method was feasible. The results of ALT and AST tests indicate that SXT has no side effect on the liver function of rats. Treatment with SXT improved cardiac function and ventricular remodelling and inhibited cardiomyocyte apoptosis and oxidative stress levels induced by CHF. Moreover, CHF caused decrease ATP synthesis, which was accompanied by a reduction in ATP 5D protein levels, damage to mitochondrial structure, abnormal glucose and lipid metabolism, and changes in the expression of PGC-1α related signal pathway proteins, all of which were significantly alleviated by treatment with SXT. Conclusion: SXT reverses CHF-induced cardiac dysfunction and maintains the integrity of myocardial structure by regulating energy metabolism. The beneficial effect of SXT on energy metabolism may be related to regulating the expression of the PGC-1α signalling pathway.

20 October 2025 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Open access
FXFengyue Xu
Fengyue Xu
FGFan Gao
Fan Gao
JTJiaye Tian
Jiaye Tian
XMXiaoxuan Mo
Xiaoxuan Mo
ZXZan Xie
Zan Xie
QGQiuhong Guo
Qiuhong Guo
YangxinDingji Capsule (YXDJ), derived from the classical Zhigancao Decoction, is widely applied in clinical practice to treat arrhythmias, alleviate myocardial injury, and protect cardiac function; however, its underlying protective mechanism remains unclear. In this study, we investigated the mechanisms underlying the cardioprotective effects of YXDJ using an integrative approach that combined metabolomics and network pharmacology. A rat model of arrhythmia was established using isoproterenol (ISO) induction. The concentrations of five core components in YXDJ, namely Liquiritigenin, Liquiritin, Rhmannioside D, Ginsenoside Re, and Ginsenoside Rg1, were quantified using HPLC-MS/MS. Metabolomic analysis based on UPLC-Q-Exactive-Orbitrap-MS was performed to identify key differential metabolites and their associated pathways. Potential targets of YXDJ core components were predicted through network pharmacology, molecular docking, and molecular dynamics simulations, and subsequently validated in vivo. The results demonstrated that the five core components of YXDJ exhibited excellent linearity within their respective concentration ranges (R2 ≥ 0.9992), along with good stability, repeatability, and recovery. Metabolomic analysis indicated that YXDJ exerted cardioprotective effects by modulating differential metabolites such as 1-Methylhistidine, sphinganine, and phytosphingosine, and by participating in pathways including Histidine metabolism and Sphingolipid metabolism. Network pharmacology, molecular docking, and molecular dynamics simulations further identified two stable complexes with high binding affinities, namely Liquiritin-SRC and Liquiritin-PTGS2. Consistently, in vivo experiments confirmed that YXDJ alleviated arrhythmia-induced myocardial injury through SRC and PTGS2, thereby exerting significant cardioprotective effects. This study suggests that the core components of YXDJ, exemplified by liquiritigenin, exert cardioprotective effects against arrhythmias by modulating SRC, PTGS2, and associated metabolic profiles. This offers new insights and a scientific basis for studying YXDJ's mechanism of action and its clinical application.

1 November 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FXFengyue Xu
Fengyue Xu
FGFan Gao
Fan Gao
JTJiaye Tian
Jiaye Tian
XMXiaoxuan Mo
Xiaoxuan Mo
ZXZan Xie
Zan Xie
QGQiuhong Guo
Qiuhong Guo

24 December 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FGFan Gao
Fan Gao
FXFeng-Yue Xu
Feng-Yue Xu
SGSheng-Yun Gao
Sheng-Yun Gao
HLHong-Jing Li
Hong-Jing Li
XZXin-Meng Zhao
Xin-Meng Zhao
XLXing-chao Liu
Xing-chao Liu

19 April 2026 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FXFengyue Xu
Fengyue Xu
FGFan Gao
Fan Gao
JTJiaye Tian
Jiaye Tian
XMXiaoxuan Mo
Xiaoxuan Mo
ZXZan Xie
Zan Xie
QGQiuhong Guo
Qiuhong Guo